VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PRPH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PRPHProPhase Labs, Inc.
$0.09$431541
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPRPHBalance Sheet

ProPhase Labs, Inc. (PRPH) Balance Sheet

30Y historyFree accessUpdated daily

The company's financial health has deteriorated rapidly, with total assets falling from $91.9 million in 2023Q4 to $59.9 million by 2025Q4, while retained earnings have plummeted to a $73.1 million deficit.

PRPH Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Current Assets3.15M30.64M47.59M60.83M61.32M15.89M9.95M18.24M28.92M9.63M11.88M13.46M11.28M10.72M13.2M15.76M17.23M20.67M28.84M29.79M30.25M24.96M23.74M22.48M22.18M23.47M30.7M47M49.2M1M
Cash & Short-Term Investments90K678K4.74M17.44M17.51M8.46M1.36M8.24M21.94M441K1.66M2.93M1.64M572K5.54M8.23M12.8M11.96M16.09M17.76M16.89M14.37M11.39M12.9M9.74M11.37M14M28.3M25.5M400K
Cash Only90K678K1.61M9.11M8.66M6.82M434K1.55M3.17M441K1.66M2.93M1.64M05.54M8.23M12.8M11.96M16.09M17.76M16.89M14.37M11.39M12.9M9.74M11.37M14M28.3M25.5M400K
Short-Term Investments003.13M8.33M8.86M1.64M926K6.69M18.77M000000000000000000000
Accounts Receivable1.54M20.06M35.81M37.05M37.71M3.15M6.82M7.8M1.95M5.77M4M5.84M5.32M5.41M3.22M4.82M2.09M4.52M6.67M6.56M7.88M6.38M7.86M4.19M4.18M4.06M6.6M7.6M10.9M600K
Days Sales Outstanding129.031.08K294.52110.27174.1379.34252.13216.8471.95100.2270.8696.5277.5688.1167.32121.3438.4280.5161.756.8253.652.9569.1551.9661.7876.5897.1476.2156.67273.75
Inventory70K1.14M2.29M3.98M4.6M3.04M1.46M1.9M1.53M2.74M4.33M3.29M2.52M2.05M2.69M1.68M1.41M3M4.81M4.26M3.9M3.45M3.75M4.53M6.51M6.92M6.2M6.5M7.7M100K
Days Inventory Outstanding8.6360.2929.7127.9136.32111.9573.3483.2370.5791.22187.61152.27110.0591.81158.99108.2462.18120.45104.3780.8355.1253.4963.7596.01247.04429.09293.9221.73131.95-
Other Current Assets1.45M8.76M4.74M2.37M1.5M1.24M304K296K2.86M417K1.88M519K501K2.69M1.75M138K138K1.19M1.27M1.22M1.58M764.36K0374.01K782.26K1.12M3.9M4.6M5.1M-100K
Total Non-Current Assets56.72M32.56M44.34M26.81M27.98M15.52M2.33M2.5M5.24M3.17M2.95M2.6M6.14M5.94M5.88M5.94M2.58M3.7M4.48M5.05M5.73M6.57M2.53M2.46M2.57M2.59M2.6M1.6M600K400K
Property, Plant & Equipment2.03M11.62M14.9M11.35M10.35M8.31M2.33M2.5M2.74M3.17M2.95M2.6M2.56M2.37M2.31M2.36M2.57M3.67M4.36M4.84M5.59M6.47M2.42M2.34M2.2M2.14M1.9M1M200K100K
Fixed Asset Turnover2.14x0.58x2.98x10.81x7.64x1.75x4.24x5.25x3.60x6.62x6.98x8.49x9.76x9.47x7.57x6.14x7.70x5.59x9.06x8.71x9.61x6.79x17.16x12.59x11.21x9.05x13.05x36.40x351.00x8.00x
Goodwill3.97M5.23M5.23M5.71M5.71M901K0000000000000000030.76K327.01K00000
Intangible Assets7.17M9.75M12.33M8.47M10.85M1.23M0000003.58M3.58M3.58M3.58M000030.76K30.76K30.76K021.94K438.87K200K300K400K200K
Long-Term Investments43.49M00002.75M0000000000026.45K26.45K26.45K026.45K00000000
Other Non-Current Assets63K5.97M4.56M1.28M1.07M2.32M002.5M000000012K9K96.76K187.2K110.86K37.39K80.36K91.37K24.19K7.3K500K300K0100K
Total Assets59.87M63.2M91.93M87.65M89.3M31.41M12.27M20.74M34.16M12.8M14.83M16.06M17.42M16.66M19.08M21.7M19.82M24.37M33.31M34.85M35.98M31.53M26.27M24.93M24.76M26.06M33.3M48.6M49.8M1.4M
Asset Turnover0.07x0.11x0.48x1.40x0.89x0.46x0.80x0.63x0.29x1.64x1.39x1.37x1.44x1.34x0.91x0.67x1.00x0.84x1.18x1.21x1.49x1.39x1.58x1.18x1.00x0.74x0.74x0.75x1.41x0.57x
Asset Growth %-5.27%-31.25%4.88%-1.84%184.33%155.87%-40.81%-39.3%166.84%-13.67%-7.65%-7.82%4.56%-12.67%-12.06%9.48%-18.68%-26.85%-4.39%-3.14%14.1%20.02%5.35%0.72%-4.99%-21.75%-31.48%-2.41%3457.14%-
Total Current Liabilities53.08M32.13M20.86M16.07M15.52M6.29M933K4.23M1.81M6.84M4.53M5.24M4.62M4.91M7.85M8.23M5.76M6.59M10.02M9.25M9.57M7.11M5.48M6.51M3.56M4.85M7.1M4M8.1M100K
Accounts Payable12.96M13.72M8.64M5.91M7.03M3.77M432K437K562K2.16M990K667K1.01M1.3M885K489K482K693.84K537.86K885.65K771.82K978.4K524.14K394.68K818.8K763.53K400K800K1.1M100K
Days Payables Outstanding1.6K723.51112.141.4555.47138.9221.7219.1125.971.8842.8930.8544.1458.0152.3531.4721.3327.8511.6716.810.9115.158.98.3731.0847.3618.9627.2918.85-
Short-Term Debt5.16M6.57M2.79M301K663K329K0001.49M0000000000428.57K428.57K00000000
Deferred Revenue (Current)1.5M1.7M2.38M2.5M2.03M169K104K206K0000000000000000000000
Other Current Liabilities50K8.03M2.6M2.93M3.92M1.52M310K3.2M1.25M3.02M3.06M4.2M3.26M3.61M6.73M7.26M4.89M5.69M9.48M8.13M7.44M4.98M2.01M1.74M1.2M4.08M6.7M3.2M7M0
Current Ratio0.06x0.95x2.28x3.78x3.95x2.52x10.66x4.31x15.96x1.41x2.62x2.57x2.44x2.18x1.68x1.91x2.99x3.13x2.88x3.22x3.16x3.51x4.33x3.45x6.24x4.84x4.32x11.75x6.07x10.00x
Quick Ratio0.06x0.92x2.17x3.54x3.65x2.04x9.10x3.86x15.11x1.01x1.66x1.94x1.89x1.77x1.34x1.71x2.75x2.68x2.40x2.76x2.75x3.03x3.65x2.76x4.41x3.41x3.45x10.13x5.12x9.00x
Cash Conversion Cycle-1.46K418.19212.1396.73154.9752.38303.76280.96116.61119.56215.59217.94143.48121.91173.96198.1179.27173.12154.4120.8597.8291.3123.99139.6277.73458.31372.07270.65169.77-
Total Non-Current Liabilities3.28M23.71M21.69M7.94M15.14M14.55M110K0001.47M100K200K300K0000001.04M2.46M524.14K394.68K911.81K763.53K400K800K1.1M100K
Long-Term Debt011.65M7.33M2.4M10.04M9.99M00001.47M00300K0000001.04M2.46M00000000
Capital Lease Obligations639K6.35M8.33M4.26M4.2M4.4M000000000000000000000000
Deferred Tax Liabilities000224K00000000000000000000000000
Other Non-Current Liabilities2M4.92M4.92M00000000100K200K300K000000000000400K00100K
Total Liabilities56.36M55.85M42.54M24.02M30.67M20.85M1.04M4.23M1.07M6.84M6M5.34M4.82M5.21M7.85M8.23M5.76M6.59M10.02M9.25M10.6M9.57M5.48M6.51M3.56M4.85M7.1M4M8.1M200K
Total Debt8.62M24.57M18.46M6.96M14.9M14.72M0001.49M1.47M0000000001.46M2.89M00000000
Net Debt8.53M23.89M16.85M-2.15M6.24M7.91M-434K-1.55M-3.17M1.05M-198K-2.93M-1.64M0-5.54M-8.23M-12.8M-11.96M-16.09M-17.76M-15.42M-11.47M-11.39M-12.9M-9.74M-11.37M-14M-28.3M-25.5M-400K
Debt / Equity2.46x3.34x0.37x0.11x0.25x1.39x---0.25x0.17x---------0.06x0.13x--------
Debt / EBITDA---0.24x1.01x---------------0.33x3.60x--------
Net Debt / EBITDA----0.07x0.42x--------2.49x--------3.52x-14.26x-10.27x--151.62x---2.86x-0.72x-
Interest Coverage-2.37x-11.64x-16.88x30.98x5.62x-6.84x---73.89x-17.81x-115.33x-782.40x32.15x-------53.78x29.70x5.70x--------
Total Equity3.51M7.35M49.38M63.63M58.63M10.56M11.23M16.5M31.85M5.96M8.83M10.72M12.6M11.45M11.23M13.46M14.06M17.77M23.3M25.59M25.37M21.96M20.79M18.42M21.2M21.21M26.2M44.6M41.7M1.2M
Equity Growth %-52.29%-85.11%-22.39%8.53%455.4%-6.01%-31.95%-48.18%434.17%-32.47%-17.61%-14.93%10%2%-16.6%-4.26%-20.9%-23.71%-8.97%0.86%15.56%5.63%12.83%-13.1%-0.04%-19.05%-41.26%6.95%3375%-
Book Value per Share0.413.8528.7034.1231.889.109.7114.4820.293.495.386.397.747.717.589.4210.8513.8018.3020.9019.0815.2013.9416.9119.7220.1023.0829.8428.400.95
Total Shareholders' Equity3.51M7.35M49.38M63.63M58.63M10.56M11.23M16.5M31.85M5.96M8.83M10.72M12.6M11.45M11.23M13.46M14.06M17.77M23.24M25.53M25.32M21.9M20.79M18.42M21.2M20.97M26.2M44.6M41.7M1.2M
Common Stock4K23K18K16K16K14K14K14K14K13K13K13K11K11K10K10K9K8.78K8.75K8.66K8.18K8.14K8.07K8.05K7.66K7.64K7.4M000
Retained Earnings-73.14M-58.39M-5.03M11.75M2.64M-3.63M-1.51M4.53M22.14M-19.69M-16.82M-13.22M-5.38M-5.79M-4.7M-1.99M1.51M5.35M10.89M13.35M15.09M11.88M11.69M11.01M17.47M17.25M22.4M26.6M19.8M-2.8M
Treasury Stock-49.64M-64M-64M-58.03M-48.41M-47.49M-47.49M-47.49M-47.02M-30.74M-30.74M-30.74M-25.64M-25.64M-25.64M-25.19M-25.19M-25.19M-25.19M-25.19M-25.19M-25.19M-25.19M-25.19M-25.19M-25.16M-25M-10.3M00
Accumulated OCI-198K-198K-300K757K-175K-11K-2K-24K-78K-5.13M-4.71M-4.34M-4.06M-3.86M-3.61M-3.39M-3.15M-4.87M-4.95M-4.03M-3.17M-1.82M-1.45M-1.02M-812.39K-520.33K-300K-200K-100K0
Minority Interest00000000000000000053.09K63.56K54.31K54.98K000237.33K0000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and insolvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2025Q4)

Rapid Erosion of Financial Stability

As reported in recent financial filings, ProPhase Labs has seen its total assets decline from $91.9 million in 2023Q4 to $59.9 million by 2025Q4, signaling a rapid contraction in the company's resource base as it struggles to pivot away from its legacy diagnostic revenue streams.

The consistent decline in total assets alongside a ballooning deficit in retained earnings suggests that the company is consuming its capital base to fund ongoing operations. This trajectory indicates that the current business model is failing to generate the necessary scale to sustain its asset footprint.

Critical Cash Runway Near Exhaustion

Based on the most recent quarterly data, ProPhase Labs reports a cash balance of only $90,000, which, when paired with a current ratio of 0.06, indicates an extremely precarious liquidity position that leaves virtually no buffer against operational shocks or unexpected liabilities in the near term.

A current ratio of 0.06 is exceptionally low and suggests that current liabilities vastly outweigh the company's ability to meet them with liquid assets. Investors should monitor this closely, as the lack of cash reserves likely necessitates immediate and potentially dilutive external financing to maintain operations.

Leverage Rising Amidst Revenue Decline

According to reported balance sheet figures, the company's debt-to-equity ratio has surged to 2.46 as of 2025Q4, reflecting a significant increase in leverage that appears driven by the necessity to fund operating losses rather than strategic growth initiatives or capital expansion projects.

The rising debt-to-equity ratio in the face of declining assets and negative retained earnings suggests that the company is increasingly reliant on debt to bridge its funding gap. This trend warrants investigation, as it increases the risk of insolvency if the company cannot secure additional capital.

Erosion of Shareholder Equity Base

As evidenced by the company's financial statements, retained earnings have plummeted to a deficit of $73.1 million by 2025Q4, indicating that years of operating losses have severely eroded the equity base and diminished the value attributable to common shareholders over the observed period.

The persistent decline in equity highlights the impact of sustained net losses on the company's balance sheet. This trend suggests that the firm's capital structure is becoming increasingly fragile, which may limit future financing options and increase the risk of significant shareholder dilution.

Hidden Risks in Asset Valuation

While the balance sheet carries $4.0 million in goodwill, the rapid decline in operational performance suggests that these intangible assets may be subject to future impairment charges, which would further weaken the company's already strained equity position and overall balance sheet health.

The presence of goodwill on the balance sheet during a period of significant revenue contraction and negative operating margins warrants further investigation. If the underlying business units fail to meet performance expectations, these assets may need to be written down, exacerbating the company's existing financial distress.

PRPH — Frequently Asked Questions

Quick answers to the most common questions about buying PRPH stock.

What are the total assets of ProPhase Labs, Inc. (PRPH)?

As of 2025, ProPhase Labs, Inc. (PRPH) had total assets of $59.9M including $3.1M in current assets.

How much debt does ProPhase Labs, Inc. (PRPH) have?

ProPhase Labs, Inc. (PRPH) carries total debt of $8.6M, offset by $0.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of ProPhase Labs, Inc.?

ProPhase Labs, Inc. (PRPH) has total shareholders' equity (book value) of $3.5M ($0.41 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is ProPhase Labs, Inc.'s current ratio and liquidity?

ProPhase Labs, Inc. (PRPH) reported a current ratio of 0.06x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.